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Abstract
Amyotrophic lateral sclerosis (ALS) is a lethal disease characterized by motor neuron degeneration and associated with aggre-
gation of nuclear RNA-binding proteins (RBPs), including FUS. How FUS aggregation and neurodegeneration are prevented 
in healthy motor neurons remain critically unanswered questions. Here, we use a combination of ALS patient autopsy tissue 
and induced pluripotent stem cell-derived neurons to study the effects of FUS mutations on RBP homeostasis. We show that 
FUS’ tendency to aggregate is normally buffered by interacting RBPs, but this buffering is lost when FUS mislocalizes to 
the cytoplasm due to ALS mutations. The presence of aggregation-prone FUS in the cytoplasm causes imbalances in RBP 
homeostasis that exacerbate neurodegeneration. However, enhancing autophagy using small molecules reduces cytoplasmic 
FUS, restores RBP homeostasis and rescues motor function in vivo. We conclude that disruption of RBP homeostasis plays 
a critical role in FUS-ALS and can be treated by stimulating autophagy.
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Introduction
Amyotrophic lateral sclerosis (ALS) is the most common 
motor neuron (MN) disease [28]. ALS pathology is char-
acterized by preferential degeneration of upper and lower 
motor neurons, which leads to progressive paralysis and 
eventually death. Since available treatments do not effec-
tively prevent or slow disease progression, novel therapeu-
tics are urgently needed.
There is increasing evidence that defects in the homeo-
stasis of RBPs, i.e. changes in their expression levels or 
subcellular localization, are critically involved in driving 
the onset of ALS. Approximately 10% of all ALS cases 
are familial, many of which have been linked to genetic 
mutations in RNA-binding proteins (RBPs), including 
Fused in sarcoma (FUS), TAR DNA-binding protein 43 
(TDP43), Matrin3, Ewing sarcoma breakpoint region 1 
(EWSR1), TATA-Box Binding Protein Associated Factor 
15 (TAF15), heterogeneous nuclear ribonucleoprotein A1 
(hnRNPA1), hnRNPA2B1, and TIA1 [15]. These RBPs 
are structurally related, containing at least one RNA-rec-
ognition motif (RRM), a nuclear localization signal (NLS), 
and a low complexity domain, which is required for phase 
separation. ALS-associated mutations accelerate an aber-
rant liquid-to-solid phase transition of these proteins [21], 
and aggregates containing RBPs have been detected in 
ALS patient MNs.
ALS patients with mutant FUS exhibit a particularly 
severe progression, with 60% of cases developing pathol-
ogy before 40 years of age. FUS mutations primarily occur 
in the NLS domain, such as P525L and R521C, inducing 
FUS cytoplasmic mislocalization due to reduced inter-
actions with the nuclear import receptor Transportin-1 
[6]. However, many questions remain: How do healthy 
motor neurons maintain FUS homeostasis? How is FUS 
homeostasis disrupted by ALS-causing FUS mutations in 
the NLS? Do FUS mutations affect other ALS-associated 
RBPs? How can the function of RBPs such as FUS be 
restored? Do the various ALS-associated RBP mutations 
each require a specific treatment? Answering these ques-
tions should contribute to the development of effective 
therapeutics for ALS patients.
In this manuscript, we use a combination of neuropa-
thology and induced pluripotent stem cell (iPSC)-derived 
neurons to study the effects of FUS mutations on protein 
homeostasis. We show that MNs in spinal cord tissue 
from ALS patients with mutant FUS express heterogene-
ous levels of cytoplasmic FUS protein, and we use gene-
edited WT and P525L FUS-eGFP iPSCs to model this 
heterogeneity. We demonstrate that the cytoplasmic mis-
localization caused by mutations in the FUS NLS impairs 
the interaction of FUS with other ALS-associated RBPs. 
Purified hnRNPA1, EWSR1, and TAF15 prevent FUS 
from undergoing an aberrant liquid-to-solid phase tran-
sition, indicating that FUS mislocalization disrupts FUS 
interactions with these RBPs, facilitating the nucleation 
of toxic cytoplasmic FUS aggregates. We additionally 
show that iPSC-derived neurons with high cytoplasmic 
FUS levels exhibit defects in protein degradation, which is 
marked by increased p62, as well as reduced protein levels 
of hnRNPA1, hnRNPA2B1, EWSR1, and TAF15, which 
we confirm using human autopsy tissue. Knocking down 
hnRNPA1, hnRNPA2B1, EWSR1, and TAF15 induces 
neurodegeneration, thus highlighting their importance 
for neuronal viability. Finally, we show that small mol-
ecules inducing autophagy restore homeostasis of all mis-
regulated proteins and ameliorate motor function in vivo. 
Taken together, our results establish that FUS-ALS pathol-
ogy is mechanistically linked to the homeostasis of mul-
tiple ALS-associated RBPs, which can be ameliorated by 
drugs inducing autophagy. Since impaired homeostasis 
is a hallmark of multiple ALS subtypes, drugs inducing 
autophagy could be effective therapeutics for many ALS 
patients.
Materials and methods
See Online Resource 1 for a complete description of all 
materials and methods.
Ethical approval
All procedures involving human participants were performed 
in accordance with the ethical standards of the institutional 
and/or national research committee as well as with the 1964 
Helsinki declaration and its later amendments.
Cell culture and treatments
iPSC-derived cell lines used in this study were previously 
characterized and cultured as described [18]. Sodium 
arsenite (0.5 mM, Fluka) and cycloheximide (100 µg/ml, 
Sigma-Aldrich) were added for 1 h. All the other treat-
ments, including torkinib (10 µM, Selleckchem), PQR309 
(10 µM, Medchem), Adox (100 µM, Santa Cruz), MG132 
(5 µM, Selleckchem), 3-MA (2.5 mM, Selleckchem) were 
performed over 24 h or 48 h. Lentivectors for shRNA-medi-
ated knockdown were generated in house as described in 
the Supplements. 90 k neurons were infected at day 10 of 
maturation with lentiviral particles in the presence of 10 µg/
ml protamine sulfate (Sigma-Aldrich). Cells were analyzed 
after another 9 days from transduction.
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Protein analysis
Cells were lysed in RIPA buffer (Santa Cruz Biotechnol-
ogy). Lysates were analyzed by capillary electrophoresis 
using the Protein Simple WES™ 12-230 Separation Mod-
ule. FUS-eGFP was immunoprecipitated using a GFP-Trap® 
Kit (Chromotek). Label-free mass spectrometric analysis of 
immunoprecipitated proteins was performed as described 
in the extended methods section attached as Supplementary 
information.
Drosophila experiments
All Drosophila stocks were maintained on standard corn-
meal at 25  °C in light/dark-controlled incubators. The 
w1118, UAS-eGFP, and D42-GAL4 were obtained from the 
Bloomington stock center. The UAS-FUS WT, UAS-FUS 
P525L, and UAS-FUS R521C flies as well as the experimen-
tal conditions for climbing index assessment were previously 
described [1].
Patient samples and staining
Human post-mortem brain and spinal cord samples (n = 6 
age-matched controls, n = 6 R521C FUS mutation) were 
obtained from the Department of (Neuro-)Pathology, Aca-
demic Medical Center (AMC), University of Amsterdam. 
All tissues were fixed in buffered formalin within 6–24 h 
from death. 3–4 µm paraffin sections were processed for 
either immunohistochemistry (DAB and haematoxylin) or 
immunofluorescent staining as previously described [7, 11]. 
Primary antibodies included: rabbit anti-FUS (AMAB90549, 
Sigma) 1:150, mouse anti-hnRNPA1 (NB100-672, Novus-
bio) 1:200, mouse anti-hnRNPA2B1 (sc-32316, Santa Cruz) 
1:200. Images were acquired with either a Zeiss Axioplan 
microscope for immunohistochemistry, or a Zeiss LSM 700 
laser scanning confocal microscope for immunofluorescence.
Results
Heterogeneity in MN populations in ALS‑patient 
spinal cord is recapitulated by FUS‑eGFP 
iPSC‑derived neurons with different linker lengths
A defining trait of ALS is the progression of motor dysfunc-
tion. Although disease onset is typically focal, symptoms 
rapidly spread in a manner that reflects the organization of 
the underlying neuronal circuitry, usually in a corticofu-
gal fashion [3, 4]. Although ALS-causing mutations affect 
genes, such as FUS, that are ubiquitously and constitutively 
expressed, MNs appear to be particularly vulnerable. Fast-
twitch fatigable α-MNs are among the first to degenerate, 
whereas other MN subtypes degenerate in later stages of the 
disease [22]. Thus, MNs do not degenerate synchronously, 
and understanding the properties that confer vulnerability to 
some neurons and resistance to others may have profound 
therapeutic value. When we immunostained human spinal 
cord tissue from ALS patients carrying the FUS-NLS muta-
tion R521C, we found that the lumbar spinal cord of FUS-
ALS cases showed severe loss of α-MNs [suppl. Figure 1 
(Online Resource 2)], and the surviving α-MNs displayed 
varying degrees of FUS protein mislocalization and cyto-
plasmic accumulation [Fig. 1a; suppl. Figure 1b (Online 
Resource 2)]. Thus, MNs of ALS patients show heterogene-
ous levels of FUS neuropathology with some MNs showing 
higher levels of FUS accumulation than others.
To better understand the molecular pathomechanisms 
driving FUS-ALS, we previously generated isogenic iPSC 
reporter lines with WT and P525L FUS-eGFP capable of 
differentiating into electrically active neurons [suppl. Fig-
ure 2 (Online Resource 2)], which consisted of a mixed 
population of spinal neurons containing 15% of bona fide 
MNs [suppl. Figure 3 (Online Resource 2)] [18]. To tag the 
FUS c-terminus of only one allele with eGFP (Fig. 1b), we 
used two different linkers, which produced distinct effects on 
the subcellular localization of the FUS protein. Using a long 
linker (LL), which was previously characterized, we found 
that WT FUS-eGFP was exclusively localized in the nucleus 
(Fig. 1c, d). In contrast, isogenic iPSC-derived neurons with 
P525L FUS-eGFP showed a two-fold increase in cytoplas-
mic FUS-eGFP fluorescent intensity (Fig. 1c, d), demon-
strating that P525L induces FUS mislocalization. However, 
FUS-eGFP mislocalization in neurons carrying the P525L 
mutation in the presence of the LL was only minor. Since 
patient MNs are heterogeneous with some showing promi-
nent FUS pathology, we also used a shorter linker stretch 
(SL), which partially interfered with the function of the adja-
cent NLS domain (Fig. 1b). For this reason, the SL caused 
a basal level of FUS-eGFP mislocalization, which was 4 
times higher than in LL lines (Fig. 1c, d). In particular, SL 
P525L iPSC-derived neurons showed the highest amount 
of cytoplasmic FUS protein, manifesting an 8-fold increase 
compared to LL WT neurons (Fig. 1c, d). Thus, we used 
these lines to recapitulate the heterogeneity found in patients 
and investigate the impact of differential FUS mislocaliza-
tion on the progression of the degenerative process.
As ALS is characterized by neurodegeneration, we 
immunostained differentiated neurons for cleaved-Caspase 
3 (CC3), which marks apoptosis (Fig. 1e). We observed that 
P525L significantly increased apoptosis in neurons with LL 
as well as SL (Fig. 1f). In addition, we observed that CC3 
levels correlated well with the amount of cytoplasmic FUS-
eGFP (Fig. 1g). Indeed, neurons with SL P525L FUS-eGFP 
showed the highest levels of cell death (Fig. 1f, g). These 
data supported a link between cytoplasmic FUS-eGFP levels 
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Fig. 1  FUS-eGFP lines used in this study recapitulate ALS pathol-
ogy observed in patients. a FUS immunoreactivity of human lumbar 
spinal cord α-MNs of FUS patients (n = 6). Intensely labelled globu-
lar inclusions (red arrowheads), diffuse cytoplasmic accumulations 
(white arrows), normal nuclear FUS immunolabelling (black arrows). 
Scale bars = 60  μM. b Schematic representation of the linkers used 
to tag endogenous FUS with eGFP. c Confocal micrographs show-
ing FUS-eGFP subcellular localization in the iPSC-derived neurons 
used in this study. Scale bar = 10  µm. d Quantification of cytoplas-
mic FUS-eGFP fluorescence intensity in the iPSC-derived neurons 
shown in c. e Immunofluorescence staining for the indicated mark-
ers. f Apoptosis in SL and LL FUS-eGFP neurons is quantified as 
percentage of cleaved Caspase 3 (CC3)-positive cells. n = 3, and for 
each independent experiment 3 confocal images were analyzed. Scale 
bar 50 µm. g Apoptosis in iPSC-derived neurons correlates with the 
amount of cytoplasmic FUS-eGFP. Linear correlation was calculated 
using Pearson’s correlation. R2 = 0.859 Error bars represent stand-
ard error of the mean (SEM). * and ** Correspond to p < 0.05 and 
p < 0.01, respectively
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and neurodegeneration, confirming that our iPSC-derived 
spinal neurons represent a suitable model to recapitulate the 
heterogeneity observed in FUS-ALS patients.
FUS‑ALS is linked to defects in protein quality 
control
Because impaired FUS homeostasis has been linked to ALS 
pathology, we used capillary electrophoresis to quantify total 
FUS protein levels (Fig. 2a, b). The results showed a sig-
nificant accumulation of FUS-eGFP protein specifically in 
iPSC-derived neurons with SL P525L (Fig. 2a). This obser-
vation led us to speculate that heterogeneity in FUS pathol-
ogy could be linked to differences in protein degradation. To 
test this hypothesis, we evaluated p62 protein levels, which 
typically increase the following defects in proteasome activ-
ity and autophagy. We found that LL WT-eGFP, LL P525L 
FUS-eGFP and SL WT FUS-eGFP neurons had p62 levels 
comparable to neurons from non-transgenic parental iPSCs 
[Fig. 2a; suppl. Figure 4a (Online Resource 2)]. In contrast, 
SL P525L FUS-eGFP neurons exhibited almost two-fold 
more p62 than WT (Fig. 2a). Thus, neurons with SL P525L 
FUS-eGFP not only presented the highest levels of cyto-
plasmic FUS, but they also displayed increased FUS-eGFP 
as well as p62 levels, suggesting defects in protein degrada-
tion. Using immunofluorescence, we observed that p62 was 
diffused throughout the soma of SL P525L neurons with 
its intensity occasionally increasing in subcellular localiza-
tions with FUS accumulation [suppl. Figure 4b, c (Online 
Resource 2)]. The correlation of p62 and FUS became more 
evident in arsenite-stressed cells, in which a subset of FUS-
eGFP stress granules (SGs) clearly co-localized with p62 
assemblies, suggesting that p62 interacts with FUS, and its 
accumulation is linked to the increment in FUS-eGFP levels 
[suppl. Figure 4d (Online Resource 2)].
Next, we looked at autophagy in our cultures. Consist-
ent with our earlier observations, combined inhibition of 
autophagy and proteasome activity in LL P525L neurons 
using 3-MA + MG132 treatment resulted in FUS-eGFP 
being strongly mislocalized and reaching cytoplasmic lev-
els similar to those of untreated SL P525L neurons [suppl. 
Figure 4a, c (Online Resource 2)]. This was accompanied by 
a significant increase in the overall levels of both FUS-eGFP 
and p62 [suppl. Figure 4a (Online Resource 2)], confirm-
ing a critical connection between cytoplasmic FUS levels 
and protein homeostasis. Importantly, when we blocked 
the autophagic flux using chloroquine, we also observed 
an increase of p62 (Fig. 2c) and LC3-II [suppl. Figure 4e 
(Online Resource 2)] in all neuronal cultures with mislo-
calized FUS-eGFP. This suggested that an impairment in 
autophagy alone without inhibiting proteasome activity is 
sufficient to induce the pathological increase in p62 levels. 
Investigating basal autophagy in our cultures, we found 
that, in addition to showing increased p62, SL P525L neu-
rons had significantly increased steady-state levels of LC3 
(Fig. 2d) as well as strongly enlarged lysosomes (Fig. 2e). 
Such morphology was previously associated with aberrant 
lysosomal dynamics [8], suggesting that ALS neurons with 
high cytoplasmic FUS levels exhibit impaired autophagy. In 
conclusion, we demonstrated that FUS ALS is characterized 
by a tight interplay between autophagic clearance, p62, and 
cytoplasmic FUS protein levels.
P525L disrupts FUS interactions with other 
ALS‑associated RBPs
We hypothesized that the mislocalization of FUS to the 
cytoplasm would alter FUS protein–protein interactions 
and that some of the affected interactions would be inte-
gral to the induction of ALS. To test this, we exploited 
the eGFP reporter sequence as an affinity tag for selective 
immunoprecipitation of FUS-eGFP, followed by analysis 
of the FUS interactome by liquid chromatography cou-
pled to tandem mass spectrometry (LC–MS/MS). To dis-
sect the impact of the FUS cytoplasmic shift, we focused 
on LL lines and compared results from LL WT FUS-eGFP 
neurons, which exhibit exclusive nuclear localization, with 
isogenic LL P525L FUS-eGFP cultures. Neurons from the 
non-transgenic parental line were also included to filter 
out non-specific interactors. In this experiment, we identi-
fied approximately 200 proteins as potential FUS interac-
tors [suppl. Table 1 (Online Resource 3)], and gene ontol-
ogy analysis showed enrichment for RNA, ribosomal and 
spliceosomal complexes [suppl. Table 2 (Online Resource 
4)], which is consistent with the known functions of FUS. 
When we specifically focused on ALS-associated proteins, 
we found that a number of FUS interaction partners encom-
passed RBPs previously described to cause familial forms 
of ALS, including hnRNPA1, hnRNPA2B1, EWSR1 and 
TAF15, were reduced in pulldown samples with P525L FUS 
compared to WT. Immunoblot confirmed the LC–MS/MS 
results and showed significantly decreased interactions of 
P525L FUS with hnRNPA1, hnRNPA2B1, EWSR1 and 
TAF15, while binding to other RBPs, such as TDP43 and 
MATR3, remained unchanged (Fig. 3a). We then extended 
our quantification to SL neurons, where hnRNPA2B1 again 
showed significantly reduced levels in P525L pulldowns 
compared to WT (Fig. 3b). Although this did not reach sta-
tistical significance, hnRNPA1, TAF15 and EWSR1 exhib-
ited a trend towards reduced interactions with P525L FUS 
(Fig. 3b). It is likely that differences in FUS interactions with 
RBPs were difficult to detect in SL neurons because SL WT 
and P525L FUS-eGFP are both mislocalized, thus negatively 
impacting on RBP enrichment in both cases. Taken together, 
these results demonstrate that P525L reduces the interaction 
between FUS and certain ALS-associated RBPs.
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ALS‑associated RBPs inhibit liquid‑to‑solid phase 
transition of FUS protein
Protein solubility plays a critical role in FUS function and 
ALS pathogenesis [21]. Phase separation of FUS into mem-
braneless compartments is required for DNA damage repair, 
mRNA transport, as well as SG formation. In addition, phase 
separation could seed the formation of aggregates in ALS 
by promoting an aberrant liquid-to-solid phase transition. It 
was previously shown that both Transportin-1 and nuclear 
RNAs can modulate FUS phase separation behavior [9, 
17]. Therefore, we sought to determine whether the interac-
tion of FUS with other RBPs may similarly impact on the 
dynamics of FUS liquid-to-solid phase transition. To test 
this, we performed an in vitro phase separation assay where 
we aged LL P525L FUS for 10 h in the presence or absence 
of RBPs (Fig. 3c). Fluorescence recovery after photobleach-
ing (FRAP) showed that P525L FUS droplets analyzed at 
0 h of age recovered rapidly, consistent with them being 
liquid (Fig. 3d). However, after 10 h of aging, P525L FUS 
had acquired a fibril-like morphology and was unable to 
recover, which suggested the formation of solid aggregates 
(Fig. 3c, d). Importantly, when P525L FUS droplets were 
aged in the presence of EWSR1, TAF15 and hnRNPA1, fiber 
formation was suppressed (Fig. 3c, d). P525L FUS interac-
tion with the investigated RBPs was confirmed by assessing 
droplet co-localization (Fig. 3e). Taken together, these data 
demonstrated that the investigated ALS-associated RBPs can 
modulate the phase behavior of FUS and inhibit aggregation. 
We conclude that the cytoplasmic shift induced by FUS NLS 
mutations reduces the interaction of FUS with nuclear RBPs, 
facilitating FUS aggregation.
ALS‑associated RBPs are post‑transcriptionally 
reduced in neurons with SL P525L FUS‑eGFP
Since FUS interacts with a number of ALS-associated RBPs 
(Fig. 4a) and functions as a protein complex, we speculated 
that high levels of cytoplasmic FUS might affect the protein 
levels of other ALS-associated RBPs. To test this, we used 
capillary electrophoresis to quantify their amounts in whole 
neuronal lysates. The investigated RBPs did not display any 
significant change between WT and P525L genotypes in LL 
neuronal cultures (Fig. 4b), confirming that the differences 
in FUS association were due to FUS mislocalization. Nota-
bly, when we analyzed SL cultures, we observed a signifi-
cant reduction of EWSR1, TAF15, hnRNPA1 and hnRN-
PA2B1 selectively in SL P525L neurons compared to WT 
(Fig. 4c). This demonstrates that high levels of cytoplasmic 
FUS in neurons lead to a reduction in the levels of certain 
ALS-associated RBPs.
ALS is a neurodegenerative disease, which implies 
that, although mutant FUS is ubiquitously expressed, ALS 
pathology has a certain degree of cell-type specificity. For 
this reason, we tested the specificity of reduced levels of 
EWSR1, TAF15, hnRNPA1 and hnRNPA2B1. To do this, 
we quantified their levels by performing immunoblotting 
using undifferentiated iPSCs as well as neural progenitors 
(NPCs). In contrast to differentiated neurons, iPSCs and 
iPSC-derived NPCs showed no differences in the levels 
of EWSR1, TAF15, hnRNPA1 and hnRNPA2B1 [suppl. 
Figure 5a, c (Online Resource 2)]. Consistent with this 
observation, p62 levels were also unchanged in iPSCs and 
iPSC-derived NPCs [(suppl. Figure 5b (Online Resource 2)], 
highlighting the significance of studying ALS in disease-
relevant cell types, such as human spinal neurons.
Because FUS levels have been suggested to modulate 
the mRNA expression of EWSR1, TAF15 and hnRNPA1 
[12], we asked whether observed changes in protein lev-
els would depend on transcriptional regulation. To test this, 
we performed RNA profiling on SL WT and P525L neu-
rons, including the untargeted parental line as a reference. 
Interestingly, we observed no significant differences in the 
expression levels of EWSR1, TAF15, hnRNPA1, and hnRN-
PA2B1 across genotypes [suppl. Table 3 (Online Resource 
5)]. We concluded that the reduction in the levels of the 
investigated ALS-associated RBPs in P525L SL FUS-eGFP 
neurons occurs at a post-transcriptional level.
Levels of ALS‑associated RBPs inversely correlate 
with FUS aggregation in ALS patient MNs
Next, we sought to relate our findings to the neuropatho-
logical alterations in FUS-ALS patients [suppl. Table 4 
(Online Resource 6)]. In iPSC-derived spinal neurons, as 
described above, we observed that FUS NLS mutations, such 
as P525L, result in FUS protein accumulation, decreased 
interaction with ALS-associated RBPs, and reduced levels of 
these RBPs. Since the investigated RBPs protected purified 
FUS from fibrillization, we hypothesized that their levels 
would inversely correlate with the presence of FUS aggre-
gates in ALS patient MNs. To test this, we used autopsy 
tissue (lumbar spinal cord and/or motor cortex) from FUS-
ALS patients and performed double immunolabelling using 
antibodies against FUS and our target RBPs. Surviving 
α-MNs harboring FUS inclusions showed reduced levels of 
hnRNPA1 and hnRNPA2B1 compared to α-MNs lacking 
FUS aggregates (Fig. 5a, c, d). Immunostainings for EWSR1 
and TAF15 also showed reduced nuclear levels in patient 
α-MNs [suppl. Figure 6 (Online Resource 2]). Interestingly, 
we also observed rare co-localization of hnRNPA1, EWSR1, 
and TAF15, but not hnRNPA2B1, with FUS aggregates in 
both α-MNs and cortical neurons [Fig. 5b as well as suppl. 
Figure 6c, d (Online Resource 2)]. Hence, FUS aggregation 
in ALS patient MNs affects other ALS-associated RBPs.
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Knockdown of ALS‑associated RBPs reduces cell 
viability
Next, we asked whether reduced levels of ALS-associ-
ated RBPs contribute to neurodegeneration. To test this, 
we generated lentivectors carrying small hairpin RNA 
(shRNA) sequences targeting EWSR1, TAF15, hnRNPA1 
and hnRNPA2B1 for gene knockdown [suppl. Figure 7 
(Online Resource 2), suppl. Figure 8a (Online Resource 
2), as well as suppl. Tables 5 and 6 (Online Resources 7 
and 8)]. We first determined knockdown efficiency using 
HEK293T cells [suppl. Figure 8b (Online Resource 2)], 
and subsequently optimized infection conditions in SL 
WT FUS-eGFP neurons [suppl. Figure 9 (Online Resource 
2)]. To evaluate neurodegeneration mediated by RBP 
knockdown, we lysed transduced neuronal cultures and 
probed the supernatant for LDH activity as a measure-
ment of cell viability. Importantly, all RBP knockdowns 
caused increased neurodegeneration compared to controls 
(Fig. 6a). In line with this finding, knockdown of each 
EWSR1, TAF15, hnRNPA1, and hnRNPA2B1, caused 
iPSC-derived neurons to develop a strongly impaired mor-
phology, as well as higher amounts of cell debris com-
pared to controls (Fig. 6b, c). Of note, although hnRNPA1 
knockdown caused a reduction in hnRNPA1 levels of only 
10%, neuronal viability was considerably reduced, under-
lying the importance of RBP homeostasis in neurons, 
where even small changes in the abundance of these pro-
teins can strongly impact on cell physiology.
We also tested the effects of reduced ALS-associated 
RBPs on FUS by quantifying FUS-eGFP fluorescence 
intensity in infected versus uninfected cells. We consist-
ently detected increased SL WT FUS-eGFP nuclear signal 
upon knockdown of each of the tested RBPs (Fig. 6d, f). 
Simultaneously, we observed a slight but not significant 
increase in cytoplasmic FUS-eGFP, which is in agreement 
with the FUS-eGFP protein having a WT NLS. These 
results further validated the interdependence between FUS 
and the investigated ALS-associated RBPs (Fig. 6e).
Inducing autophagy reduces accumulated P525L 
FUS and restores RBP homeostasis
We described that ALS patient MNs show heterogenous 
levels of FUS mislocalization, and we used iPSC-derived 
spinal neurons to model this heterogeneity. We showed that 
inhibition of autophagy increases the accumulation of cyto-
plasmic FUS, and we demonstrated that FUS accumulation 
is linked to a number of pathological phenotypes involv-
ing other ALS-associated RBPs. This led us to speculate 
that stimulating autophagy would facilitate the clearance 
of mislocalized FUS and restore protein homeostasis. To 
this end, we treated our neuronal cultures with the mTOR 
inhibitor torkinib. Because torkinib inhibits mTOR directly 
by preventing ATP binding, it induces autophagy in neu-
rons more potently than rapamycin [(suppl. Figure 4f, g 
(Online Resource 2)], which uses a more indirect mechanism 
involving FKBP12 [18]. Quantification of FUS-eGFP sig-
nal fluorescence intensity demonstrated that torkinib treat-
ment significantly reduced cytoplasmic FUS-eGFP levels 
compared to controls (Fig. 7a). Consistent with the reduc-
tion in cytoplasmic FUS-eGFP, we found that P525L neu-
rons treated with torkinib displayed decreased FUS-eGFP 
recruitment to arsenite-induced cytoplasmic SGs compared 
to controls [suppl. Figure 10a (Online Resource 2)]. In addi-
tion, SL P525L neurons are characterized by an increased 
FUS aggregation propensity relative to WT, and torkinib 
induced a trend of amelioration [suppl. Figure 10b (Online 
Resource 2)]. Using capillary electrophoresis, we observed a 
time-dependent increase in EWSR1, TAF15, hnRNPA1, and 
hnRNPA2B1 protein levels upon torkinib treatment (Fig. 7c, 
d). In addition, torkinib decreased p62 levels by about 50% 
compared to untreated controls (Fig. 7c, d). Finally, we 
report that torkinib moderately improved survival of neurons 
with SL P525L FUS-eGFP (Fig. 7e). Taken together, these 
data demonstrated that inducing autophagy using torkinib 
promotes protein homeostasis as well as neuronal survival.
Since mTOR inhibition can also suppress protein synthe-
sis, it could be argued that the effects of torkinib on FUS-
eGFP levels are due to suppression of translation rather than 
increased autophagy. To rule this out, we evaluated FUS-
eGFP translation rates by measuring FUS-eGFP recovery 
after photobleaching of whole neuronal cell bodies. Results 
showed that torkinib did not slow down FUS-eGFP sig-
nal recovery, confirming that FUS translation rates are not 
altered by the treatment (Fig. 7b), which corroborates the 
beneficial role of torkinib in stimulating FUS clearance by 
autophagy.
Although torkinib restored protein homeostasis in spinal 
neuronal cultures, torkinib does not cross the blood–brain 
barrier, thus limiting its use as an oral ALS therapeutic 
(although intrathecal delivery might be possible). Nev-
ertheless, mTOR is a clinically validated drug target, and 
Fig. 3  The cytoplasmic mislocalization induced by P525L causes 
reduced FUS binding to several ALS-associated RBPs, promoting 
aggregation. a, b Western blot analysis of FUS protein interactors in 
a LL and b SL neurons after FUS-eGFP immunoprecipitation reveals 
differential interactions with several ALS-associated partners. n = 4. 
Error bars indicate SEM. *, **, and *** Correspond to p < 0.05, 0.01, 
and 0.001, respectively. c In  vitro phase separation assay showing 
fibrillization of purified P525L LL FUS-eGFP protein in the presence 
or absence of distinct RBPs. Investigated RBPs effectively prevent 
FUS fibril formation. d Fluorescence recovery after photobleaching 
(FRAP) was used to assess the dynamics of P525L LL FUS at the 
tested conditions for the indicated time points. RBPs promote the 
maintenance of a liquid-like behavior. e Co-localization of P525L LL 
FUS with the reported RBPs. Scale bar 5 µm
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brain penetrant inhibitors are being actively developed. 
One example is PQR309, which is currently in phase II 
clinical trials for cancer treatment [31]. Consistent with 
our results using torkinib, we found that PQR309 reduced 
the amount of P525L FUS-eGFP recruited to SGs in neu-
rons treated with arsenite, indicating effective autophagic 
clearance of cytoplasmic FUS-eGFP [suppl. Figure 10a 
(Online Resource 2)]. In addition, PQR309 significantly 
diminished FUS aggregation measured by filter trap assay 
[(suppl. Figure 10b (Online Resource 2)] and restored 
homeostasis of ALS-associated RBPs as well as p62 in 
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Fig. 4  Relationship between FUS and the identified ALS-associated 
RBPs. a Proximity ligation assay confirms FUS interaction with 
EWSR1, TAF15, hnRNPA1 and hnRNPA2B1 in iPSC-derived neu-
rons. Protein–protein interactions appear as distinct spots. Scale 
bar = 25  µm. b, c WES capillary electrophoresis for quantification 
of the overall cellular levels of the RBPs found to interact with FUS 
in LL b, c SL neurons. Analysis reveals a significant decrease in 
EWSR1, TAF15, hnRNPA1 and hnRNPA2B1 levels, which is spe-
cific to P525L FUS SL neurons. n = 5. Error bars indicate SEM. *, 
**, and *** Correspond to p < 0.05, 0.01, and 0.001, respectively
Fig. 5  Immunohistochemistry of human tissue from FUS-ALS 
patients. a–d Double immunolabelling using FUS antibody together 
with a–c hnRNPA1 and d hnRNPA2B1 in human FUS-ALS lumbar 
spinal cord compared to normal age-matched controls. n = 6. Nuclear 
hnRNPA1and FUS immunoreactivity in normal control α-MNs 
(white arrow head, left panel). Surviving α-MNs in FUS-R521C 
cases containing FUS aggregates show low hnRNPA1 levels (white 
arrows), while MNs without FUS aggregates display normal levels 
(white arrowheads). Normal nuclear co-localization of hnRNPA1 
with FUS (white arrowhead) in a control case; rare co-localization 
of cytoplasmic hnRNPA1 accumulations with FUS aggregates (red 
arrowhead) in b α-MNs and c motor cortex. Scale bars 15 µm
▸
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iPSC-derived neurons [suppl. Figure 10c (Online Resource 
2)]. Therefore, compounds inducing autophagy, such as 
torkinib and PQR309, could be attractive for treating ALS.
Autophagy stimulation decreases motor 
dysfunction in vivo
Drosophila models have been instrumental in examining 
genetic and small molecule modifiers of neurodegenera-
tive diseases, including FUS-ALS. Similar to ALS patients, 
P525L FUS-ALS flies exhibit heterogeneous cytoplasmic 
FUS levels (Fig. 8a). We aimed at demonstrating that knock-
ing down RBPs exacerbates FUS pathogenesis in flies analo-
gous to human neurons. Overexpression of either human WT 
FUS, which models a mutation in the 3′ untranslated region 
of FUS that upregulated FUS protein [25], or R521C in the 
fly eye resulted in degeneration (Fig. 8b, c). Consistent with 
our results using human neurons, RNAi against HRD98DE, 
which is the fly orthologue of hnRNPA1 and hnRNPA2B1, 
exacerbated the eye phenotype (Fig. 8b, c). Additionally, it 
was previously reported that knocking down Cabeza, which 
is the fly ortholog of human FET proteins FUS, EWSR1, 
and TAF15, causes neurodegenerative phenotypes in flies, 
including decreased adult viability, locomotor disabilities at 
both larval and adult stage, as well as reduced lifespan [30]. 
As expected, knocking down Cabeza rescued eye degenera-
tion in flies overexpressing FUS (Fig. 8b, c).
Next, we tested if autophagy stimulation would ame-
liorate ALS phenotypes in vivo. To do this, Drosophila 
models of FUS-ALS were treated with torkinib. Selective 
overexpression of human WT FUS as well as two disease-
causing mutations (R521C and P525L) in fly MNs caused 
severe motor dysfunction, as evident from reduced climb-
ing ability (Fig. 8e). When we treated flies with two dif-
ferent concentrations (10 and 50 µm) of torkinib to induce 
autophagy (Fig. 8d), we found that treated animals showed 
a dose-dependent significant improvement in their climbing 
abilities (Fig. 8e), indicating that autophagy stimulation had 
suppressed FUS-induced motor dysfunction.
Discussion
Multiple RBPs, including FUS, EWSR1, TAF15, hnRNPA1 
and hnRNPA2B1 have been associated with ALS. Each of 
these RBPs has a low-complexity intrinsically disordered 
domain, which is prone to aggregation, and aggregates of 
these proteins are found in patients. One critical question 
is how healthy cells inhibit pathological phase transitions 
and maintain protein homeostasis. It was previously shown 
that FUS interactions with Transportin-1, as well as the high 
RNA concentrations in the nucleus prevent FUS aggrega-
tion in healthy cells and that ALS mutations disrupt these 
mechanisms [9, 17]. Here, we showed that mislocalization of 
FUS also disrupts its interactions with other ALS-associated 
RBPs that normally prevent FUS aberrant liquid-to-solid 
phase transition. Thus, although each of these proteins are 
individually prone to aggregation, mixing them together, as 
would be found in the nucleus of healthy neurons, buffers 
FUS against phase transition.
Here, we demonstrated that FUS-ALS is not solely 
restricted to FUS dysfunction and aggregation, but rather 
affects the homeostasis of a number of other ALS-associated 
RBPs. We showed that MNs in the spinal cord of FUS-ALS 
patients are heterogeneous in their degree of cytoplasmic 
FUS accumulation, supporting the idea of a progressive 
pathology. However, since FUS aggregates were described 
not to contain EWSR1 and TAF15 [20], it has long been 
thought that FUS-ALS pathology is primarily about FUS 
aggregation and does not affect other ALS-associated RBPs, 
implying that these ALS subtypes are essentially independ-
ent of each other. Instead, we showed that the presence of 
aggregation-prone FUS in the cytoplasm causes imbalances 
in RBP homeostasis, leading to a reduction in the nuclear 
levels of EWSR1, TAF15, hnRNPA1 and hnRNPA2B1, 
which exacerbates FUS pathogenesis and accelerates neu-
rodegeneration. Using post mortem tissue from FUS-ALS 
patients, we observed that MNs with FUS aggregates also 
exhibit reduced overall levels of certain ALS-associated 
RBPs compared to MNs lacking FUS aggregation. Of note, 
reduced levels of hnRNPA1 and hnRNPA2B1 have been 
reported in cases of Alzheimer’s disease [2], suggesting a 
connection between RBP homeostasis and neuronal health 
in multiple disorders. Importantly, we demonstrated that 
this phenotype was not detectable in NPCs or undifferenti-
ated iPSCs, highlighting the significance of studying ALS 
in human spinal neurons.
FUS-ALS accounts for approximately 35% of all patients 
developing the disease before 40 years of age, whereas muta-
tions in other ALS genes, including C9ORF72, SOD1 and 
Fig. 6  Reduction in RBP levels synergistically contributes to neuro-
degeneration. a Cell viability assay performed on neurons infected 
with either empty or knockdown vectors shows reduced viabil-
ity following knockdown of the indicated RBP. A, B and C refer 
to three individual shRNA vectors, each targeting the indicated 
RBP. n = 3. Error bars indicate SEM. *, **, ***, and **** Corre-
spond to p < 0.05, 0.01, 0.001, and 0.0001, respectively. b For each 
knockdown, a representative confocal micrograph of the culture is 
shown. Infected cells are identified by tdTomato expression. Scale 
bar = 50  µm. c Quantification of cell debris abundance following 
neuronal death induced by RBP knockdown. Results from the three 
individual vectors for each knocked-down protein were combined and 
compared to the empty vector. n = 3. d, e Mean fluorescence intensity 
of d nuclear and e cytoplasmic FUS-eGFP in iPSC-derived neurons 
after RBP knockdown. f Representative confocal micrographs. Scale 
bar 10 µm. n = 3. Error bars indicate SEM. * and ** Correspond to 
p < 0.05 and 0.01, respectively
◂
 Acta Neuropathologica
1 3
0
1
2
hnRNPA1 protein levels
*
20%
0
1
2
3
*
70%
0
1
2
EWSR1 protein levels
*
40%
0
1
2
TAF15 protein levels
*
30%
0
1
2
p62 protein levels
**
50%
0
1
2
Matr3 protein levels
Fo
ld
 to
 u
nt
re
at
ed
FUS-eGFP
EWSR1
hnRNPA1
hnRNPA2B1
p62
MATR3
GAPDH
Un
tre
ate
d
To
rki
nib
 24
h
To
rki
nib
 48
h
100 kDa
117 kDa
90 kDa
100 kDa
37 kDa
34 kDa
62 kDa
37 kDa
68 kDa TAF15
P525L
P525L
+ Torkinib
D
N
A
PF
Ge-S
UF
3
B
B
UT
Fo
ld
 to
 u
nt
re
at
ed
Fo
ld
 to
 u
nt
re
at
ed
Fo
ld
 to
 u
nt
re
at
ed
Fo
ld
 to
 u
nt
re
at
ed
Fo
ld
 to
 u
nt
re
at
ed
WT
P5
25
L
P5
25
L +
To
rki
nib
0.0
0.5
1.0
1.5
2.0
Cytoplasmic FUS-eGFP
*
Fo
ld
 to
 W
T
a b
c
d
0 20 40 60 80 10
0
12
0 14
0
16
0
18
0
0.0
0.5
1.0
1.5
2.0 FUS translation rates after FRAP
Time (min)
M
ea
n 
in
te
ns
ity
(a
.u
.)
Untreated
Torkinib 24h
CHX
To
rki
nib
_2
4h
Un
tre
ate
d
To
rki
nib
_4
8h
To
rki
nib
_2
4h
Un
tre
ate
d
To
rki
nib
_4
8h
To
rki
nib
_2
4h
Un
tre
ate
d
To
rki
nib
_4
8h
To
rki
nib
_2
4h
Un
tre
ate
d
To
rki
nib
_4
8h
To
rki
nib
_2
4h
Un
tre
ate
d
To
rki
nib
_4
8h
To
rki
nib
_2
4h
Un
tre
ate
d
To
rki
nib
_4
8h
e
SL
 P
52
5L
 n
eu
ro
ns
hnRNPA2B1 protein levels
Untreated Torkinib
C
le
av
ed
 C
as
pa
se
 3
0
5
10
15
20
%
of
C
C
3+
ce
lls
Apoptosis
Un
tre
ate
d
To
rki
nib
p = 0.06
Acta Neuropathologica 
1 3
TDP43, are much more common in older patients [26]. 
Additionally, some FUS mutations are associated with 
rapidly progressing juvenile forms emerging in the late 
teens and early twenties [26], including P525L. The unique 
aggressiveness of FUS-ALS might be linked to the involve-
ment of so many RBPs, which synergistically contribute to 
neurodegeneration.
One interesting open question is the molecular mecha-
nism by which the accumulation of cytoplasmic FUS leads 
to decreased levels of ALS-associated RBPs, including 
EWSR1, TAF15, hnRNPA1, and hnRNPA2B1. Transcrip-
tional feedback may be a possibility, and one study described 
a transcriptional interdependency between FUS, EWSR1, 
TAF15 and hnRNPA1 [12]. However, this did not seem to 
be the case in our hands since RNA levels were unchanged. 
Another possibility is that RBP levels may be reduced by 
translational suppression, which was recently suggested by 
studies in a FUS mouse model [16]. Translational suppres-
sion could be linked to RNP granules, which act as sites 
for mRNA storage and/or degradation. This is particularly 
intriguing since FUS is a component of RNP granules, and 
mutant FUS causes RNP granules to aberrantly accumulate. 
However, explaining the specificity for EWSR1, TAF15, 
hnRNPA1 and hnRNPA2B1 is challenging, particularly 
when it has been found that FUS interacts with more than 
5500 RNA targets, including the RBPs we investigated [13]. 
Interestingly, all of these RBPs, unlike TDP43 and Matrin3, 
have been experimentally validated as cargos for mamma-
lian Transportin-1, which was described to play a role in P 
body formation and in the transport of specific cargoes to 
other RNP granules [29]. Thus, Transportin-1 might be a key 
player in this scenario. Finally, it is possible that RBP levels 
are reduced by protein degradation or excretion, for example 
by exosomes [10] or exophers [19]. Further experiments are 
needed to test these hypotheses.
Our results place impaired protein dynamics at the core 
of ALS pathogenesis, and we conclude that it is critical to 
restore appropriate levels of all ALS-associated RBPs to 
prevent neurodegeneration. A protein-specific gene therapy 
approach is unlikely to be effective since multiple ALS-asso-
ciated RBPs were reduced by aberrantly accumulated mutant 
FUS, and the levels of these proteins are tightly regulated in 
neurons, with either too much or too little being toxic [5]. 
In our work, we demonstrated that stimulating autophagy 
could be an effective therapeutic to rescue protein homeo-
stasis. We showed that spinal neurons with accumulated 
FUS are marked by increased p62 protein levels, suggest-
ing defects in protein degradation, and, consistent with this, 
we observed aberrant lysosomal morphology. Importantly, 
stimulating autophagy with torkinib and PQR309 facilitated 
the clearance of cytoplasmic FUS and restored the levels of 
the investigated ALS-associated proteins. In line with these 
findings, small molecule-mediated induction of autophagy 
ameliorated MN function in Drosophila models of ALS. 
This implies that drugs modulating autophagy would likely 
be most effective when administered before protein aggre-
gation initiates, which is presumably when patients are 
still asymptomatic. In this context, compounds inducing 
autophagy could be an effective strategy to protect neurons 
against the onset of FUS-ALS. Since defects in autophagy 
have been associated with both familial and sporadic ALS 
cases [14, 23], we propose that modulating autophagy could 
be an effective therapeutic for many ALS patients.
However, critical issues, including potential side effects 
and limitations, remain to be addressed before patients are 
treated with autophagy-enhancing drugs because induc-
ing autophagy has occasionally been reported to exacer-
bate ALS in some models. For example, mTOR inhibi-
tion causes immunosuppression and was only beneficial 
in SOD1 G93A mice when lymphocytes were depleted 
[27, 32]. A possible strategy to overcome this would be 
to develop therapeutics capable of inducing autophagy 
in an mTOR-independent manner. Interestingly, it has 
been shown that autophagy plays different roles in MNs 
in SOD1 G93A mice depending on the disease stage 
[24]. Consistent with our findings, inhibiting autophagy 
accelerated muscle denervation and the onset of motoric 
phenotypes. However, later in the disease course, inhib-
iting autophagy unexpectedly prolonged survival. This 
suggests that, while autophagy stimulation may be a suc-
cessful strategy for some ALS patients, any therapeutic 
approach must take into account multiple factors, includ-
ing the genetic background, disease stage, and possibly 
other context-dependent influences.
Fig. 7  Autophagic clearance of aberrantly accumulated cytoplas-
mic FUS restores protein homeostasis and ameliorates survival of 
SL P525L iPSC-derived neurons. a Confocal micrographs showing 
FUS-eGFP distribution before and after Torkinib treatment (above). 
Arrowhead indicates FUS-eGFP cytoplasmic accumulation in 
untreated neurites; arrow shows reduced FUS-eGFP cytoplasmic sig-
nal following torkinib treatment. Quantification of cytoplasmic FUS-
eGFP signal intensity in acquired images (below) confirms clearance 
of mislocalized FUS-eGFP protein. Scale bar = 10 µm. b FRAP anal-
ysis performed on untreated versus torkinib-treated neurons shows 
comparable dynamics of FUS-eGFP recovery. n = 3. Error bars indi-
cate SEM. CHX = cycloheximide. c WES capillary electrophoresis 
and d corresponding quantification of the indicated proteins in P525L 
SL neurons before and after torkinib treatment. Autophagy stimula-
tion restores physiological levels. n = 4. Error bars indicate SEM. * 
and ** Correspond to p < 0.05 and 0.01, respectively. e 6 h of torkinib 
reduces apoptotic cell death identified by cleaved Caspase 3 staining. 
Scale bar = 50 µm
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Fig. 8  Drosophila models of FUS-ALS confirm the involvement 
of RBPs and are rescued by autophagy. a Localization of WT and 
P525L FUS-RFP in Drosophila larval brain. b WT and R521C FUS 
ectopic expression causes eye degeneration, which is rescued by 
cabeza RNAi and worsened by Hrb98DE RNAi. c Quantifications 
of eye degeneration. d Compared with or DMSO treated controls, 
Drosophila larvae fed with torkinib show autophagy induction in their 
brains as marked by increased Lysotracker Red staining. e Drosophila 
climbing assay showing improved fly climbing ability upon torkinib 
treatment at the indicated concentrations
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